Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Xeris Biopharma Holdings (XERS) Return on Sales: 2021-2025

Historic Return on Sales for Xeris Biopharma Holdings (XERS) over the last 5 years, with Sep 2025 value amounting to -0.06%.

  • Xeris Biopharma Holdings' Return on Sales rose 28.00% to -0.06% in Q3 2025 from the same period last year, while for Sep 2025 it was -0.06%, marking a year-over-year increase of 28.00%. This contributed to the annual value of -0.27% for FY2024, which is 11.00% up from last year.
  • Per Xeris Biopharma Holdings' latest filing, its Return on Sales stood at -0.06% for Q3 2025, which was up 54.82% from -0.13% recorded in Q2 2025.
  • Over the past 5 years, Xeris Biopharma Holdings' Return on Sales peaked at -0.06% during Q3 2025, and registered a low of -2.64% during Q3 2021.
  • Moreover, its 3-year median value for Return on Sales was -0.34% (2024), whereas its average is -0.33%.
  • Data for Xeris Biopharma Holdings' Return on Sales shows a peak YoY soared of 162bps (in 2022) over the last 5 years.
  • Xeris Biopharma Holdings' Return on Sales (Quarterly) stood at -2.47% in 2021, then soared by 162bps to -0.86% in 2022, then surged by 48bps to -0.38% in 2023, then increased by 11bps to -0.27% in 2024, then rose by 28bps to -0.06% in 2025.
  • Its Return on Sales was -0.06% in Q3 2025, compared to -0.13% in Q2 2025 and -0.20% in Q1 2025.